Skip to main content

and
  1. Article

    Open Access

    Venetoclax for Treating Chronic Lymphocytic Leukaemia: An Evidence Review Group Perspective of a NICE Single Technology Appraisal

    Venetoclax is licensed to treat relapsed or refractory (R/R) chronic lymphocytic leukaemia (CLL). As part of the Single Technology Appraisal (STA) ID944, the National Institute for Health and Care Excellence (...

    Hema Mistry, Chidozie Nduka, Martin Connock, Jill Colquitt in PharmacoEconomics (2018)

  2. No Access

    Article

    Pembrolizumab for Previously Treated Advanced or Metastatic Urothelial Cancer: An Evidence Review Group Perspective of a NICE Single Technology Appraisal

    Pembrolizumab is an intravenously administered monoclonal antibody licensed for locally advanced or metastatic urothelial carcinoma after platinum-containing chemotherapy. This summary presents the perspective...

    Daniel Gallacher, Xavier Armoiry, Peter Auguste, Rachel Court in PharmacoEconomics (2019)

  3. Article

    Open Access

    Correction to: Venetoclax for Treating Chronic Lymphocytic Leukaemia: An Evidence Review Group Perspective of a NICE Single Technology Appraisal

    Open Access This article is distributed under the terms of the Creative Commons Attribution-Non Commercial 4.0 International License (http://creativecommons.org/licenses/by-nc/4.0/

    Hema Mistry, Chidozie Nduka, Martin Connock, Jill Colquitt in PharmacoEconomics (2019)

  4. No Access

    Article

    Autologous Chondrocyte Implantation with Chondrosphere for Treating Articular Cartilage Defects in the Knee: An Evidence Review Group Perspective of a NICE Single Technology Appraisal

    Chondrosphere (Spherox) is a form of autologous chondrocyte implantation (ACI). It is licensed for repair of symptomatic articular cartilage defects of the femoral condyle and the patella of the knee with defe...

    Xavier Armoiry, Ewen Cummins, Martin Connock, Andrew Metcalfe in PharmacoEconomics (2019)